Harrow Health Q1 Revenue Misses, Loss $0.74

Harrow Health posted Q1 loss of $0.74 per share and revenue $44.2 million, missing consensus estimates of $0.35 loss and $52.55 million revenue.
Revenue shortfall stemmed from an $8 million non‑recurring gross‑to‑net adjustment tied to new VEVYE commercial coverage.
VEVYE achieved record prescriptions, with new scripts up 25% and total scripts up 11% sequentially, capturing ~14% market share.
Harrow forecasts Q2 revenue $71‑$81 million and full‑year 2026 revenue $350‑$365 million, reaffirming guidance above analyst consensus.